Photodynamic therapy-Photofrin

Phase 3Small molecule

Photodynamic therapy-Photofrin is one of 7 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hilar CholangiocarcinomaActive, not recruiting

Hilar CholangiocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Hilar Cholangiocarcinoma

#DrugCompanyPhaseTrials

Photofrin

PPinnacle Biologics Inc.

Adrucil

Beyfortus

1 4

Gemzar

Johnson & Johnson

Phase 2

1 5

LDK378

Novartis

Phase 2

1 6

Photodynamic therapy-Photofrin

CConcordia Laboratories Inc.

Phase 3

1 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Terminated·CConcordia Laboratories Inc.·Phase 3·NCT02082522·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Photodynamic therapy-Photofrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Photodynamic therapy-Photofrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Photodynamic therapy-Photofrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Concordia Laboratories Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CConcordia Laboratories Inc.

Photodynamic therapy-Photofrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News